We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The following is a round-up of share dealings by London-listed company directors and managers announced in the past w ...
GSK PLC 01 November 2024 GSK plc Total Voting Rights and Capital In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the...
GSK PLC 30 October 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Lady Susan Symonds b) Position/status PCA of...
GSK PLC on Wednesday backed its full-year guidance following "another quarter of sales and core operating profit grow ...
GSK PLC 30 October 2024 GSK on track to deliver 2024 outlooks with further good progress made in R&D Q3 2024 sales and core earnings growth driven by strong performance of Specialty...
GSK PLC on Tuesday said that it has signed a deal to buy CMG1A46 from Chimagen Biosciences for USD300 million upfront ...
based pharmaceutical and biotechnology - Tests of Arexvy, GSK's vaccine against respiratory syncytial virus, shows it ...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -29.5 | -2.10714285714 | 1400 | 1452 | 1368.5 | 9715521 | 1403.3442201 | DE |
4 | -76.5 | -5.28680027643 | 1447 | 1559.5 | 1368.5 | 8452088 | 1454.09754966 | DE |
12 | -223.5 | -14.0213299875 | 1594 | 1678 | 1368.5 | 7602907 | 1532.1232221 | DE |
26 | -365.5 | -21.0541474654 | 1736 | 1820 | 1368.5 | 7632144 | 1576.66867541 | DE |
52 | -21.3 | -1.53039229774 | 1391.8 | 1820 | 1368.5 | 7661469 | 1576.35741948 | DE |
156 | -203.3 | -12.917778625 | 1573.8 | 1824.4 | 1283.2 | 8616330 | 1536.23435696 | DE |
260 | -346.1 | -20.1619480368 | 1716.6 | 1857 | 1190.8 | 8776424 | 1517.4569066 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions